Copyright
©The Author(s) 2025.
World J Gastroenterol. Jan 7, 2025; 31(1): 101463
Published online Jan 7, 2025. doi: 10.3748/wjg.v31.i1.101463
Published online Jan 7, 2025. doi: 10.3748/wjg.v31.i1.101463
Group | No. | Sex | Age in years | Duration of medication in days | Symptom of AE | Successful eradication | Cure rate |
First-line treatment, | 008 | M | 67 | 10 | Forgot1 | No | 1/4 |
079 | F | 62 | 7 | Abdominal pain | No | ||
090 | F | 72 | 7 | Skin rash | No | ||
242 | F | 79 | 4 | Skin rash | Yes | ||
Rescue treatment, n = 2 | 073 | F | 68 | 10 | Abdominal discomfort | Yes | 2/2 |
122 | F | 60 | 10 | Skin rash | Yes |
- Citation: Gao W, Li JW, Ye H, Zhang XZ, Liu JX, Cheng H. Real-world evidence on the efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori treatment in elderly patients. World J Gastroenterol 2025; 31(1): 101463
- URL: https://www.wjgnet.com/1007-9327/full/v31/i1/101463.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i1.101463